HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00

Mural Oncology (NASDAQ:MURA) had its price target decreased by investment analysts at HC Wainwright from $18.00 to $6.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 308.16% from the company’s current price.

Several other analysts have also recently issued reports on MURA. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research note on Tuesday. Morgan Stanley downgraded Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday. Finally, Raymond James downgraded Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective on the stock. in a report on Tuesday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Stock Down 61.6 %

Shares of NASDAQ:MURA opened at $1.47 on Wednesday. The business has a fifty day simple moving average of $3.87 and a 200-day simple moving average of $3.61. Mural Oncology has a 52 week low of $1.37 and a 52 week high of $5.12. The company has a market cap of $25.33 million, a P/E ratio of -0.16 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter in the prior year, the firm posted ($3.57) earnings per share. Sell-side analysts expect that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors and hedge funds have recently modified their holdings of MURA. Commerce Bank purchased a new position in Mural Oncology in the 3rd quarter worth approximately $39,000. FMR LLC boosted its stake in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after purchasing an additional 11,423 shares during the period. Point72 Asset Management L.P. acquired a new stake in Mural Oncology during the 3rd quarter valued at $340,000. Geode Capital Management LLC increased its stake in Mural Oncology by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after buying an additional 4,731 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Mural Oncology in the 4th quarter worth $181,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.